- Remdantry™ (previously known as Inflectra®), developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar infliximab in Canada and will be commercially available across Canada as of April 1, 2025
- Celltrion offers a full-service patient support program offering a wide range of services from financial assistance to patient education in Canada
Celltrion, Inc., a leading global biopharmaceutical company, announced that Remdantry™ will be available in Canada as of April 1, 2025. Remdantry™, previously known as Inflectra®, is the new brand name for its first monoclonal antibody biosimilar to Remicade (infliximab) in Canada.
Celltrion received Health Canada Notice of Compliance (NOC) for Remdantry on March 7, 2025.
Remdantry™ will use the same Drug Identification Number (DIN) as Inflectra®, and the formulation, indications and dosages of Remdantry™ will remain the same as that of Inflectra®, which was originally approved by the Health Canada for the treatment of rheumatoid arthritis (RA), plaque psoriasis (PsO), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) in January 2014 and for Crohn’s disease (CD), fistulising Crohn’s disease and ulcerative colitis (UC) in June 2016.1
“The availability of Remdantry™ in Canada is a step forward in Celltrion’s long-standing commitment to providing ongoing support to Canadian patients who have been using our products for years,” said Jungyong Shin, Managing Director at Celltrion Healthcare Canada. “Celltrion has a long-standing track record of manufacturing Inflectra® for over 10 years and will continue to provide Remdantry™ to the Canadian market as planned. Given that the product will be sourced from South Korea, Celltrion does not anticipate any disruptions to the supply chain from external market factors, including tariffs considerations, ensuring a steady and uninterrupted availability for Canadian patients.”
Celltrion offers CELLTRION CONNECT™, a patient support program tailored to support patients and healthcare providers. The program provides guidance with reimbursement navigation, financial assistance, infusion and nurse support services for patients throughout their treatment.
In Canada, Celltrion has received Health Canada approval for six biosimilars including: Remdantry™, Remsima® SC, Yuflyma®, Vegzelma™, SteQeyma® and Omlyclo™.
Discover the latest trends and insights—explore the Business Insights Journal for up-to-date strategies and industry breakthroughs!
